Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02494713 · ClinicalTrials.gov registry record · Phase 2
Hormonal Therapy and Chemotherapy Followed by Prostatectomy in Patients With Prostate Cancer
A Phase 2 study, sponsored by The University of Texas Health Science Center, Houston.
- Terminated
- Registry status
- Phase 2
- Development phase
- 4
- Enrollment target
NCT02494713: Clinical Trial Phase 2 study, sponsored by The University of Texas Health Science Center, Houston.
NCT02494713 is a Phase 2 study that was terminated before completion, run by The University of Texas Health Science Center, Houston. The registered enrollment target is 4 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (97% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02494713, a Phase 2 study, was terminated before completion, sponsored by The University of Texas Health Science Center, Houston.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 4 participants
- Enrollment target
Study Summary
This is a study for men who have locally-advanced prostate cancer and are eligible to undergo prostatectomy. Standard treatment is prostatectomy alone, but there is a chance that cancer may spread to other organs in the future, even after the prostate is removed. If this were to occur, standard treatment would be androgen deprivation therapy (ADT; hormone therapy that blocks testosterone) plus chemotherapy. Clinical trials suggest that neoadjuvant treatment (treatment given before primary therapy) may prevent a recurrence. The purpose of this research study is to assess the safety and benefit of ADT plus chemotherapy given before prostate removal.
Primary Outcome
Pathologic response is defined by percentage of tumor burden remaining at time of prostate removal. Percentage of tumor burden is measured based on a pathologist's assessment of the prostate tissue removed and visual estimate of how much tumor there is in the prostate.
Interventions
- DRUG Docetaxel
- DRUG Doxorubicin
- DRUG Degarelix
- DRUG Ketoconazole
- DRUG Estramustine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 4 participants |
| Start Date | 2015-10 |
| Est. Completion | 2017-09-14 |
| Phase | Phase 2 |
Why NCT02494713 stopped before completion
NCT02494713 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 4 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (97% lower).
The record links to 0 conditions, and to 5 interventions - of which Docetaxel is the first listed.
NCT02494713 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02494713 about?
NCT02494713 is a clinical study titled "Hormonal Therapy and Chemotherapy Followed by Prostatectomy in Patients With Prostate Cancer". This is a study for men who have locally-advanced prostate cancer and are eligible to undergo prostatectomy. Standard treatment is prostatectomy alone, but there is a chance that cancer may spread to other organs in the future, even after the prostate is removed. If this were to occur, standard trea...
What is the current status of trial NCT02494713?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 4 participants. The study started on 2015-10. Estimated completion is 2017-09-14.
What interventions are being tested in trial NCT02494713?
The interventions under investigation include: Docetaxel (DRUG), Doxorubicin (DRUG), Degarelix (DRUG), Ketoconazole (DRUG), Estramustine (DRUG).
Who is sponsoring clinical trial NCT02494713?
This trial is sponsored by The University of Texas Health Science Center, Houston, which has 732 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02494713's enrollment target sits among peer trials
4 2001st of 2000 the lowest of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia